Swedish Institute for Infectious Disease Control, Solna, Sweden.
APMIS. 2009 Dec;117(12):912-22. doi: 10.1111/j.1600-0463.2009.02554.x.
The prevalence of IgG ELISA antibodies against pertussis toxin (anti-PT) was studied in two Swedish seroepidemiological studies. One was performed in 1997 when the new pertussis vaccination program was 1 year old (n = 3420). In 2007, when Pa vaccines had been used countrywide for 10 years in the universal child vaccination program, this study was repeated to analyze the effect of vaccination on anti-PT prevalence (n = 2379). Before the statistical analysis of seroprevalence, children vaccinated within the last 2 years before the serosurveys were excluded. The results indicate a reduced exposure to Bordetella pertussis in the population. The proportion of sera without measurable anti-PT antibodies increased significantly, aggregated over all comparable age groups, from 3.8% in people sampled in 1997 to 16.3% in people sampled in 2007. For cord blood, 1% was without measurable anti-PT antibodies in 1997 compared to a significantly higher level, 12%, in 2007. With anti-PT concentrations of > or =50 and > or =100 EU/ml as cutoff points for 'recent infection' the proportion above the cutoff points for younger children was significantly higher in 1997 than in 2007 at both cutoff points. For all adults, 20 years of age and older, the difference in proportions above the lower cutoff point was close to statistically significant, comparing 1997 with 2007. This was not the case at 100 EU/ml. In the 1997 samples of children, there was a significant downward trend of 'recent infections' at both cutoff points for three sampled age groups between 5 and 15 years of age from 21% at 5.0-5.5 years of age to 7% at 14.7-15.7 years for the lowest cutoff. In the 2007 samples of children, on the contrary, there was a significant continuous upward trend of 'recent infections', at both cutoff points, for four sampled age groups between 4 and 18 years of age - from 4% at 4-5 years of age to 16% at 17-18 years at the lowest cutoff. The continuous increase, with age of children with high anti-PT concentrations, supports the recent change in the general Swedish childhood vaccination program to include a pre-school booster at 5-6 years and a school-leaving booster at 14-16 years of age.
在两项瑞典血清流行病学研究中,研究了针对百日咳毒素 (抗-PT) 的 IgG ELISA 抗体的流行情况。一项是在新的百日咳疫苗接种计划实施 1 年时(1997 年)进行的(n=3420)。2007 年,全国范围内已在儿童常规免疫接种计划中使用百白破疫苗 10 年,重复该研究以分析疫苗接种对抗-PT 流行率的影响(n=2379)。在对血清流行率进行统计分析之前,排除了在血清学调查前 2 年内接种疫苗的儿童。结果表明人群中接触百日咳博德特氏菌的情况减少。无可测量抗-PT 抗体的血清比例显著增加,在所有可比年龄组中聚集,从 1997 年抽样人群的 3.8%增加到 2007 年抽样人群的 16.3%。对于脐血,1997 年无可测量抗-PT 抗体的比例为 1%,而 2007 年显著更高,为 12%。以抗-PT 浓度>或=50 和>或=100 EU/ml 作为“近期感染”的截断值,对于年龄较小的儿童,两个截断值处高于截断值的比例在 1997 年均显著高于 2007 年。对于所有成年人,20 岁及以上,在较低截断值处,1997 年与 2007 年相比,高于该截断值的比例接近统计学意义。在 100 EU/ml 处则不然。在 1997 年儿童样本中,对于 5 至 15 岁的三个采样年龄组,两个截断值处的“近期感染”呈显著下降趋势,从 5.0-5.5 岁时的 21%下降到 14.7-15.7 岁时的 7%。相反,在 2007 年儿童样本中,四个采样年龄组(4 至 18 岁)的“近期感染”在两个截断值处均呈显著连续上升趋势-从 4-5 岁时的 4%上升到 17-18 岁时的 16%。随着儿童抗-PT 浓度的增加,年龄的不断增加,支持瑞典儿童常规免疫接种计划最近的改变,即在 5-6 岁时增加学前加强针,在 14-16 岁时增加离校加强针。